(2)
New York, New York (Newsfile Corp. - February 23, 2021) - PCG Digital Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SNGX) is fast approaching a new drug application (NDA) submission and potential FDA approval for SGX301 (synthetic hypericin), a photodynamic treatment option to battle the debilitating effects of cutaneous T-Cell lymphoma (CTCL).
The most recent treatment option in their rare disease pipeline, SGX301, will potentially be known as HyBryte following an FDA approval. Soligenix already has the key management and marketing plan in place for seamless commercialization, a rarity in the pharmaceutical world.
Dynamik für die digitale Transformation / Zweite Frankfurt Digital Finance Konferenz etabliert sich als Treffpunkt für die digitale Finanzindustrie in Europa
mittelstandcafe.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mittelstandcafe.de Daily Mail and Mail on Sunday newspapers.
Für T-Systems steht die Cloud jetzt an erster Stelle
it-business.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from it-business.de Daily Mail and Mail on Sunday newspapers.